Literature DB >> 15872343

Automatic detection and size quantification of infarcts by myocardial perfusion SPECT: clinical validation by delayed-enhancement MRI.

Piotr J Slomka1, David Fieno, Louise Thomson, John D Friedman, Sean W Hayes, Guido Germano, Daniel S Berman.   

Abstract

UNLABELLED: We aimed to validate the accuracy of a new automated myocardial perfusion SPECT quantification based on normal limits for detection and sizing of infarcts, using delayed-enhancement MRI (DE-MRI) as a gold standard.
METHODS: Eighty-two immediate (201)Tl rest scans and 26 (201)Tl delayed redistribution scans were compared with resting DE-MRI scans acquired within 24 h of SPECT acquisition. The immediate (201)Tl scans were considered for validation of infarct detection and the delayed (201)Tl scans were considered for infarct sizing. A simplified quantification scheme was used in which defect extent (EXT) and total perfusion deficit (TPD) parameters were derived automatically from SPECT images by comparison with sex-matched normal limits and applying a 3.0 average deviation criterion. The total extent of hyperenhancement expressed as the percentage of the left ventricle was derived from DE-MRI images by visual definition of myocardial contours and defects. DE-MRI and SPECT images were fused in 3 dimensions for visual comparison. Phantom data were also quantified using the same EXT and TPD measures for defects ranging from 5% to 70% of the myocardium.
RESULTS: The area under the receiver-operator-characteristic curve for the detection of infarct on immediate rest scans was 0.91 +/- 0.03 for EXT and 0.90 +/- 0.03 for TPD (P = not significant). The sensitivity and specificity for the detection of infarct by EXT on immediate (201)Tl rest scan were 87% and 91%, respectively, with the optimal defect size threshold of 4%. Six of 7 cases with DE-MRI defects < 5% were detected by SPECT. Infarct sizes obtained from DE-MRI correlated well with EXT (slope = 0.94, offset = 3.8%; r = 0.84) and TPD (slope = 0.75, offset = 4.2%; r = 0.85) obtained from delayed SPECT (201)Tl scans. Excellent correlation was observed between the SPECT quantification and the physical defect size for the phantom data. The actual size of the defect was better estimated by EXT (slope = 1.00, offset 1.33%; r = 0.99) than by TPD (slope = 0.79, offset = 1.9%; r = 0.99).
CONCLUSION: Automated quantification of the EXT on myocardial perfusion SPECT images can reliably detect infarcts and measure infarct sizes.

Entities:  

Mesh:

Year:  2005        PMID: 15872343

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Multimodality image registration with software: state-of-the-art.

Authors:  Piotr J Slomka; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

2.  Quantitation of infarct size in patients with chronic coronary artery disease using rest-redistribution Tl-201 myocardial perfusion SPECT: correlation with contrast-enhanced cardiac magnetic resonance.

Authors:  David S Fieno; Louise E J Thomson; Piotr Slomka; Aiden Abidov; John D Friedman; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2007-01       Impact factor: 5.952

3.  Spillover Compensation in the Presence of Respiratory Motion Embedded in SPECT Perfusion Data.

Authors:  P Hendrik Pretorius; Michael A King
Journal:  IEEE Trans Nucl Sci       Date:  2008       Impact factor: 1.679

Review 4.  Quantitative Clinical Nuclear Cardiology, Part 1: Established Applications.

Authors:  Ernest V Garcia; Piotr Slomka; Jonathan B Moody; Guido Germano; Edward P Ficaro
Journal:  J Nucl Med       Date:  2019-11       Impact factor: 10.057

5.  Selvester QRS score and total perfusion deficit calculated by quantitative gated single-photon emission computed tomography in patients with prior anterior myocardial infarction in the coronary intervention era.

Authors:  Satoshi Kurisu; Takashi Shimonaga; Hiroki Ikenaga; Noriaki Watanabe; Tadanao Higaki; Ken Ishibashi; Yoshihiro Dohi; Yukihiro Fukuda; Yasuki Kihara
Journal:  Heart Vessels       Date:  2016-08-03       Impact factor: 2.037

6.  Multicenter Study on the Diagnostic Performance of Native-T1 Cardiac Magnetic Resonance of Chronic Myocardial Infarctions at 3T.

Authors:  Guan Wang; Sang-Eun Lee; Qi Yang; Vignesh Sadras; Suraj Patel; Hsin-Jung Yang; Behzad Sharif; Avinash Kali; Ivan Cokic; Guoxi Xie; Mourad Tighiouart; Jeremy Collins; Debiao Li; Daniel S Berman; Hyuk-Jae Chang; Rohan Dharmakumar
Journal:  Circ Cardiovasc Imaging       Date:  2020-06-08       Impact factor: 7.792

7.  Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy.

Authors:  Christopher Uebleis; Stefan Hellweger; Rüdiger Paul Laubender; Alexander Becker; Hae-Young Sohn; Sebastian Lehner; Alexander Haug; Peter Bartenstein; Paul Cumming; Serge D Van Kriekinge; Piotr J Slomka; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-03       Impact factor: 9.236

8.  Clinical values of left ventricular mechanical dyssynchrony assessment by gated myocardial perfusion SPECT in patients with acute myocardial infarction and multivessel disease.

Authors:  Sang-Geon Cho; Zeenat Jabin; Ki Seong Park; Jahae Kim; Sae-Ryung Kang; Seong Young Kwon; Geum-Cheol Jeong; Minchul Song; Jong Sang Kim; Jae Yeong Cho; Hyun Kuk Kim; Ho-Chun Song; Jung-Joon Min; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-18       Impact factor: 9.236

Review 9.  Automated Quantitative Nuclear Cardiology Methods.

Authors:  Manish Motwani; Daniel S Berman; Guido Germano; Piotr Slomka
Journal:  Cardiol Clin       Date:  2015-10-20       Impact factor: 2.213

Review 10.  Quantitative Clinical Nuclear Cardiology, Part 1: Established Applications.

Authors:  Ernest V Garcia; Piotr Slomka; Jonathan B Moody; Guido Germano; Edward P Ficaro
Journal:  J Nucl Cardiol       Date:  2019-10-25       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.